---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-064585"
form_type: "8-K"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2026-05-20T21:00:24+00:00"
generated_at: "2026-05-20T21:04:42.143526+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Liminatus Pharma to acquire InnocsAI in stock merger valued at ~$320M

## Summary
- 1.6B shares at $0.20/share ($320M aggregate) plus contingent value rights of 20% of future net proceeds from asset sale.
- Assets include CAR-T pipeline: IBC101 (Phase 1/2a in Korea for DLBCL) and preclinical INC101 for solid tumors.
- CEO Chris Kim also controls Valetudo Therapeutics LLC, a member of InnocsAI, making the transaction a related-party deal.
- Closing targeted by Dec 31, 2026, subject to stockholder approvals and other customary conditions.
- Liminatus to file a registration statement/proxy statement for the stockholder vote.

## SEC filing metadata
- accession: 0001104659-26-064585
- form_type: 8-K
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2026-05-20T21:00:24+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465926064585/0001104659-26-064585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465926064585/tm2615228d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-064585
- JSON: https://secwatch.observer/filing/0001104659-26-064585.json
- Plain text: https://secwatch.observer/filing/0001104659-26-064585.txt

## Key facts
- Material Agreements
  Liminatus Pharma, Inc. entered into Merger Agreement with InnocsAI LLC valued at 1,600,000,000 shares of the Company’s common stock, at an issue price of $0.20 per share (effective 2026-05-17).
  - Action: entry
  - Agreement: merger
  - Counterparty: InnocsAI LLC
  - Value: 1,600,000,000 shares of the Company’s common stock, at an issue price of $0.20 per share
  - Effective: 2026-05-17
  source text: On May 17, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a Merger Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”) with InnocsAI LLC, Delaware limited liability company (“InnocsAI”), and NamChul Jung, an individual, as the representative of the members of InnocsAI.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971387/000110465926064585/0001104659-26-064585-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.